期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 26, 期 3, 页码 543-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2012.01.009
关键词
Angiogenesis; Gynecologic cancer; Antiangiogenic drugs; Bevacizumab
资金
- NCI-DHHS-NIH [T32 CA101642]
- Gynecologic Cancer Foundation
- National Institutes of Health [CA 109298, P50 CA083639, P50 CA098258, CA128797, RC2GM092599, U54 CA151668]
- Ovarian Cancer Research Fund, Inc.
- DOD [OC073399, W81XWH-10-1-0158, BC085265]
- Baylor College of Medicine
- MD Anderson Cancer Center
- Zarrow Foundation
- Marcus Foundation
- Blanton-Davis Ovarian Cancer Research Program
- Laura and John Arnold Foundation
- RGK Foundation
- Betty Ann Asche Murray Distinguished Professorship
Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据